期刊
JOURNAL OF PSYCHOPHARMACOLOGY
卷 27, 期 4, 页码 358-365出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881112473789
关键词
Antipsychotics; baseline BMI; BMI; schizophrenia; weight
资金
- Eli Lilly and Company
The aim was to explore weight and body mass index (BMI) changes by baseline BMI in patients completing three years of monotherapy with various first-and second-generation antipsychotics in a large cohort in a post hoc analysis of three-year observational data. Data were analyzed by antipsychotic and three baseline BMI bands: underweight/normal weight (BMI <25 kg/m(2)), overweight (25-30 kg/m(2)) and obese (>30 kg/m(2)). Baseline BMI was associated with subsequent weight change irrespective of the antipsychotic given. Specifically, a smaller proportion of patients gained >= 7% baseline bodyweight, and a greater proportion of patients lost >= 7% baseline bodyweight with increasing baseline BMI. For olanzapine (the antipsychotic associated with highest mean weight gain in the total drug cohort), the percentage of patients gaining >= 7% baseline weight was 45% (95% CI: 43-48) in the underweight/normal weight BMI cohort and 20% (95% CI: 15-27) in the obese BMI cohort; 7% (95% CI: 6-8) of the underweight/normal cohort and 19% (95% CI: 13-27) of the obese cohort lost >= 7% baseline weight. BMI has an association with the likelihood of weight gain or loss and should be considered in analyses of antipsychotic weight change.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据